• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

Combination therapy of a monoclonal antibody and atorvastatin may help patients reach target LDL levels

bys25qthea
November 21, 2012
in Cardiology, Chronic Disease
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD

Key study points: 

  1. A monoclonal antibody to PCKS9 (an enzyme that degrades LDL receptors) in combination with atorvastatin significantly reduced LDL after 8 weeks of use compared to atorvastatin alone.

Primer: Cardiovascular disease is one of the major causes of death in North America. One of the risk factors contributing to its increasing incidence is high cholesterol; specifically, a low-density lipid (LDL) level greater than 100 mg/dL is associated with an increased risk of heart disease.

As many North Americans are unable to meet this target with diet alone, many drugs have been developed to decrease the amount of LDL cholesterol within plasma. Statins, for example, have the potential of lowering LDL plasma levels by about 20 to 50%.

However, there is a small contingent of patients who still do not reach the recommended levels with statin therapy. An alternative therapeutic strategy might include targeting a protein called serum proprotein convertase subtilisin/kexin 9 (PCSK9). Its function is to bind to LDL receptors in tissues such as the liver and cause their degradation, which reduces the removal of LDL cholesterol from the blood stream.

The purpose of this phase 2 study was to determine whether SAR236553, an antibody that binds to PCSK9 and keeps it from interacting with the LDL receptor, in combination with atorvastatin, could decrease LDL levels in patients who could not reach target cholesterol levels.  

RELATED REPORTS

PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis

2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]

Background reading:  

  1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
  2. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

This [double-blind, phase II randomized controlled] study evaluated the use of high or low dose atorvastatin with SAR236553 vs. high dose atorvastatin with placebo. Patients received a subcutaneous shot of the monoclonal antibody or placebo every 2 weeks.

There was a significant reduction in plasma LDL from baseline when comparing the high dose atorvastatin plus the antibody vs. the control group (73.2% vs. 17.3%, p<0.001). This trend was also seen in other cholesterol measures such as Apolipoprotein B, non-HDL cholesterol and total cholesterol. All patients who used the monoclonal antibody achieved LDL < 100 mg/dL compared to 52% in the control group.

In sum: The authors showed that patients who used an antibody to a degrader of LDL-receptors in combination with atorvastatin had significantly greater reductions in LDL than patients who used atorvastatin alone.

Some limitations of this study include the small number of patients (~30 in each arm), the length of the study (8 weeks) and the exclusion of patients with diabetes and prior cardiovascular events. Furthermore, this study only measured decreases in LDL instead of hard endpoints like the number of cardiovascular events. The phase 3 trial would do well to further elucidate these points before we consider treating patients with the antibody.  

Click to read the study in the NEJM (New England Journal of Medicine) 

By [JC] and [MP] 

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Previous Post

[Physician Comment] Recurrent early Lyme disease is caused by reinfection, not relapse

Next Post

Cardiopulmonary exercise testing is safe for high-risk cardiovascular patients

RelatedReports

Amyloidosis collage: a heart and a kidney threaded with fine teal fibers, a folded paper strip and a magnifying glass
2MM Trial Briefs

PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis

November 16, 2026
Collage of medical tech icons circling a central chip with 'AI Roundup' title and 2 Minute Medicine logo in teal background.
AI Roundup

2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]

November 16, 2026
A senior woman looks thoughtfully, accompanied by a DNA helix, a brain illustration, and cellular motifs, representing Alzheimer's genetic research.
Chronic Disease

Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways

November 15, 2026
A senior woman looks thoughtfully at a balance scale with a stethoscope and a heart illustration, symbolizing the assessment of cardiovascular risk and treatment decisions.
Cardiology

Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease

November 14, 2026
Next Post

Cardiopulmonary exercise testing is safe for high-risk cardiovascular patients

Low molecular weight heparin most effective at reducing rate of venous thromboembolism in patients undergoing bariatric surgery

Increase in white matter hyperintensities seen in migraine patients

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis
  • 2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]
  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.